Viral cell transformation is a complex phenomenon where certain viruses have the ability to alter the normal growth and behavior of host cells, leading to cellular transformation. This process is particularly associated with oncoviruses, viruses that can induce the formation of cancerous cells. During viral cell transformation, viral genes or proteins interfere with the host cell's regulatory mechanisms, promoting uncontrolled cell growth and evasion of normal cellular checkpoints. This can result in the formation of tumors and contribute to the development of various cancers. Examples of viruses associated with cell transformation include human papillomavirus (HPV), Epstein-Barr virus (EBV), and hepatitis B and C viruses. These viruses are implicated in cervical cancer, Burkitt's lymphoma, and hepatocellular carcinoma, respectively. Viral oncoproteins, such as the E6 and E7 proteins of HPV, can disrupt the functions of tumor suppressor proteins and promote genomic instability. Understanding the mechanisms of viral cell transformation is crucial for developing strategies to prevent and treat virus-induced cancers, highlighting the intersection of virology and cancer biology.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States